Last reviewed · How we verify
NCT04358276
Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study
NA trial testing Computer-Assisted Intervention in Skin Carcinoma in 840 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2026
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 840 |
| Start date | 30 October 2020 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Computer-Assisted Intervention
- Dermatoscope
- Educational Intervention
- Educational Intervention (Physician)
- Questionnaire Administration
- Text Message — full drug profile →
Conditions studied
- Skin Carcinoma — all drugs for Skin Carcinoma →
Sponsor
City of Hope Medical Center
Who can join
18 and older, any sex, with Skin Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies the impact of a 12-month invention focused on early detection of skin cancer and timely follow up in patients who underwent stem cell transplant and their primary care providers. Some stem cell transplant survivors may develop complications related to the treatment they received. Many of these complications may not be known for years after the treatment and preventive measures can be taken to reduce the chances that a complication will occur and encourage early detection. This study focuses on one complication that stem cell transplant survivors are at high risk of developing - skin cancer. An early diagnosis of skin cancer is important since the cancer is usually smaller, requires less extensive treatments, and has better outcomes. Teaching skin self-examination and encouraging patients to alert doctors to skin changes may provide an important opportunity for early detection of skin cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH).
Armenian SH, Lindenfeld L, Iukuridze A, Echevarria M, et al · · 2020 · PMID 32746799 · DOI 10.1186/s12885-020-07232-2
Verify or expand the search:
- PubMed search for NCT04358276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Computer-Assisted Intervention
Trials testing the same drug.
- NCT07206589 — Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial · NA · not yet recruiting
- NCT05018208 — Remote Monitoring in Cancer Care: A Platform Study · completed
- NCT02511821 — Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients Wi · NA · completed
- NCT02378012 — iPad Use in Reducing Anxiety and Depression in Patients Undergoing Bone Marrow Transplant · NA · terminated
- NCT03457480 — Text Messages in Preventing Tobacco Use in Young Adults · NA · completed
Other recruiting trials for Skin Carcinoma
Currently open trials in the same condition.
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT04475640 — Cancer Genetic Testing in Ethnic Populations · NA · recruiting
- NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M · Phase 2 · active not recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04358276 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04358276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing